Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
clinical_inquiry_hub@lilly.com


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Medical Conditions

Atherosclerosis
Renal Insufficiency, Chronic
Cardiovascular Diseases
Kidney Diseases
Diabetes Mellitus, Type 2
Heart Diseases
Coronary Artery Disease
Cerebrovascular Disorders
Peripheral Arterial Disease
Death
Kidney Failure, Chronic


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Apr 2024 Feb 2029

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Administered SC

Intervention Arm Group : Retatrutide;

Intervention Type : DRUG
Intervention Description : Administered SC

Intervention Arm Group : Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Ipswich Hospital
    Ipswich
    IP4 5PD
  • Musgrove Park Hospital
    Taunton
    TA1 5DA
  • University Hospital Coventry & Warwickshire
    Coventry
    CV2 2DX
  • Royal London Hospital
    London
    E1 1BB
  • Hull Royal Infirmary
    Hull
    HU3 2JZ
  • Swansea University
    Swansea
    SA2 8PP
  • Aberdeen Royal Infirmary
    Aberdeen
    AB25 2ZN
  • Altnagelvin Area Hospital
    Londonderry
    BT47 6SB
  • FutureMeds - Birmingham
    Birmingham
    B21 9RY
  • Newquay Health Centre
    Newquay
    TR7 1RU
  • FutureMeds Teesside - Middlefield Centre
    Stockton-on-Tees
    TS19 8PE
  • Ashton Medical Group - Chapel House
    Lancashire
    OL6 6EW
  • Homecroft Surgery
    Redruth
    TR16 4ET
  • FutureMeds - Liverpool
    Bromborough
    CH62 6EE
  • Futuremeds-Newcastle
    Newcastle
    NE6 1SG
  • Rame Group Practice
    Torpoint
    PL11 2TB
  • FutureMeds Glasgow - CPS Research
    Glasgow
    G20 7BE
  • Moorgreen Hospital
    West End
    SO30 3JB

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
clinical_inquiry_hub@lilly.com



The study is sponsored by Eli Lilly and Company




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT06383390
Last updated 26 August 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.